{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Atrial fibrillation"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Fatigue"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Infections and infestations - Other, specify"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Infusion related reaction"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Lung infection"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Lymphocyte count decreased"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Pancreatitis"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Pruritus"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Skin infection"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Syncope"}],"denoms":[{"counts":[{"groupId":"OG000","value":"35"}],"units":"Participants"}],"description":"Only adverse events that are possibly, probably or definitely related to study drug are reported.","groups":[{"description":"Patients receive isatuximab intravenously (IV) on days 1, 8, 15, and 22 of course 1 and on days 1 and 15 of subsequent courses. Treatment repeats every 28 days for 24 courses in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Isatuximab"}],"paramType":"NUMBER","populationDescription":"Participants who completed at least one day of treatment.","reportingStatus":"POSTED","timeFrame":"From date of enrollment until progression or death due to any cause, whichever occurs first, assessed up to 4 years","title":"To Evaluate Toxicities in the Treatment of Relapsed/Refractory AL Amyloidosis With Isatuximab.","type":"SECONDARY","unitOfMeasure":"Participants"}